scholarly article | Q13442814 |
P2093 | author name string | Kioussis D | |
Meier W | |||
Hochman PS | |||
Majeau GR | |||
Jimmo B | |||
P433 | issue | 6 | |
P407 | language of work or name | English | Q1860 |
P304 | page(s) | 2753-2767 | |
P577 | publication date | 1994-03-01 | |
P1433 | published in | Journal of Immunology | Q3521441 |
P1476 | title | Mechanism of lymphocyte function-associated molecule 3-Ig fusion proteins inhibition of T cell responses. Structure/function analysis in vitro and in human CD2 transgenic mice | |
P478 | volume | 152 |
Q28478230 | A biophysical model of cell adhesion mediated by immunoadhesin drugs and antibodies |
Q73882481 | A multimeric form of soluble recombinant sheep LFA-3 (CD58) inhibits human T-cell proliferation |
Q37686066 | Advances in immunosuppression for renal transplantation. |
Q35868862 | Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis |
Q33757065 | Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris |
Q35834649 | BAFF binds to the tumor necrosis factor receptor-like molecule B cell maturation antigen and is important for maintaining the peripheral B cell population |
Q36827134 | Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir? |
Q26824580 | Cellular targeting in autoimmunity |
Q45884948 | Development and application of a real-time PCR method for pharmacokinetic and biodistribution studies of recombinant adenovirus |
Q36688075 | Disrupted splenic architecture, but normal lymph node development in mice expressing a soluble lymphotoxin-beta receptor-IgG1 fusion protein. |
Q59136962 | Evidence That Combination Therapy With CD16-Bearing NK-92 Cells and FDA-Approved Alefacept Can Selectively Target the Latent HIV Reservoir in CD4+ CD2hi Memory T Cells |
Q37123276 | High levels of CD2 expression identify HIV-1 latently infected resting memory CD4+ T cells in virally suppressed subjects. |
Q36763565 | Novel targeted therapies for eosinophilic disorders |
Q33530942 | Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept |
Q52007397 | Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. |
Q35579427 | Psoriasis treatment: current and emerging directed therapies |
Q37196716 | Receptor-directed therapy of T-cell leukemias and lymphomas |
Q39178547 | Role of Memory T Cells in Allograft Rejection and Tolerance |
Q34149246 | Selective Targeting of Human Alloresponsive CD8+ Effector Memory T Cells Based on CD2 Expression |
Q36661303 | The safety and efficacy of alefacept in the treatment of chronic plaque psoriasis. |
Q57177957 | Under-Evaluated or Unassessed Pathogenic Pathways in Autoimmune Hepatitis and Implications for Future Management |
Q37600436 | Use of Alefacept for Preconditioning in Multiply Transfused Pediatric Patients with Nonmalignant Diseases |
Search more.